Recent Updates — ZJYL
Jin Medical International Ltd. completed the closing of transactions related to its Variable Interest Entity (VIE) structure by finalizing the transfer of 80% equity interest in Zhongjin Kangma Information Technology (Jiangsu) Co., Ltd. from Changzhou Zhongjin Medical Co., Ltd. This completion occurred on October 19, 2026, fulfilling obligations under the VIE Control Master Acquisition Agreement dated September 8, 2026. Consequently, Jin Medical is not required to issue 622,123 Class A ordinary shares that were previously contemplated as substitute consideration if the equity transfer had not been completed by October 31, 2026. The transaction does not result in any additional share issuance or change to the aggregate consideration under the agreement. Jin Medical International Ltd. operates in the medical device and healthcare sector.
Jin Medical International Ltd. completed the acquisition of contractual control over Huaxia Qiying (Beijing) Technology Co., Ltd. via a Variable Interest Entity arrangement on September 24, 2026. The aggregate purchase price was US$159,415,729, comprising share consideration and non-share assets including HTFX Investment Assets, Changzhou Muchi Investment Assets, Taizhou Muchi Investment Assets, Kangma Debt, and Kangma Equity. To fund the transaction, the Company issued 71,282,488 Class A ordinary shares to sellers and 8,479,560 Class A ordinary shares as financial advisory compensation. Post-closing, total outstanding shares increased to 158,194,533. The transfer of Kangma Equity remains pending with a deadline of October 31, 2026; failure to complete will result in the issuance of 622,123 substitute shares. Jin Medical International Ltd. operates in the medical technology and healthcare equipment industry.
On September 8, 2026, Jin Medical International Ltd. entered into a VIE Control Master Acquisition Agreement to acquire contractual control over Huaxia Qiying and its subsidiaries for aggregate consideration of US$159,415,729. The Company will issue 71,282,488 Class A ordinary shares as primary consideration. Concurrently, the Company transferred investment assets valued at US$4,194,167 and RMB119,079,718 to the Seller Controlling Person and executed agreements transferring an 80% equity interest in Zhongjin Kangma. The transaction includes a financial advisory fee of US$15,941,572.90 payable in shares at $1.88 per share. Closing is subject to customary conditions including Nasdaq notification and PRC legal clearance. Jin Medical International Ltd. operates in the healthcare sector, focusing on elderly-care and rehabilitation products.
Jin Medical International Ltd. completed a VIE control acquisition of Beijing Tongsheng Technology Co., Ltd. on July 21, 2026, issuing 64,186,456 Class A Ordinary Shares to the seller and 6,418,646 shares for financial advisory services. The company also reported unaudited first-half fiscal year 2026 results showing total revenue of $8.9 million, a 9.7% decrease from the prior year period, driven by lower sales to its largest Japanese customer and discontinued electric scooter sales due to regulatory qualification issues. Gross margin improved to 26.9% as operating expenses rose to $3.0 million, resulting in a net loss of $0.2 million compared to a net income of $0.01 million previously. The company maintains $9.1 million in cash and $21.0 million in short-term investments while executing a 1-for-20 reverse stock split effective March 16, 2026. Jin Medical International Ltd. operates in the medical equipment industry, designing, manufacturing, and selling wheelchairs and living aids for people with disabilities.
Jin Medical International Ltd. shareholders approved several significant corporate restructuring and acquisition-related proposals on July 20, 2026. Key approvals include increasing Class B ordinary share voting rights from 30 to 800 votes per share, increasing authorized share capital to US$15,005,000, and a VIE-based acquisition of Beijing Tongsheng Technology Co., Ltd. through the issuance of 64,186,456 Class A ordinary shares at US$1.641 per share. Additionally, the company approved a share repurchase and share issuance involving Jolly Harmony Enterprises Limited. Jin Medical International Ltd. operates in the medical device industry, specializing in products for the treatment of respiratory and respiratory-related conditions.
Dr. Jiayuan (James) Tong has resigned from his position as an independent director and Chairperson of the Nominating and Corporate Governance Committee, effective July 9, 2026. The Board has appointed Ning Xue to fill the vacancy, effective July 14, 2026, to serve as an independent director and Chairperson of the Nominating and Corporate Governance Committee. Jin Medical International Ltd. is a medical device manufacturer.